Investment Thesis
FEMY is a pre-commercial/early-stage medical device company with severe operational burn. Operating cash outflow of $4.1M annually against $424.9K revenue represents an unsustainable 9.6x burn-to-revenue ratio, providing approximately 1.3 years of cash runway at current burn rates. While 40.8% YoY revenue growth and zero debt are positive signals, the company lacks a clear path to profitability without dramatic revenue acceleration or material cost reduction.
Strengths
- Strong revenue growth of 40.8% YoY demonstrates market adoption potential
- Healthy balance sheet with no long-term debt and $5.4M cash reserves
- Excellent liquidity position with 3.91x current ratio and 1.98x quick ratio
Risks
- Massive operating cash burn of -$4.1M annually against only -$424.9K revenue is fundamentally unsustainable
- Limited cash runway of approximately 1.3 years at current burn rate without additional financing
- Company remains in pre-profitable stage with operating margin of -994% and no clear inflection point
- Data quality concerns including impossible >100% gross margins and net income positive despite operating losses suggest potential accounting anomalies or one-time gains masking operational weakness
Key Metrics to Watch
- Quarterly operating cash flow trend and year-over-year change in cash burn rate
- Revenue growth acceleration to demonstrate pathway to positive unit economics
- Operating expense reduction or gross margin improvement to show progress toward profitability
Financial Metrics
Revenue
424.9K
Net Income
846.1K
EPS (Diluted)
$0.00
Free Cash Flow
-4.2M
Total Assets
16.5M
Cash
5.4M
Profitability Ratios
Gross Margin
131.1%
Operating Margin
-994.0%
Net Margin
199.1%
ROE
11.6%
ROA
5.1%
FCF Margin
-993.8%
Balance Sheet & Liquidity
Current Ratio
3.91x
Quick Ratio
1.98x
Debt/Equity
0.00x
Debt/Assets
55.8%
Interest Coverage
-11.68x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:07:14.963478 |
Data as of: 2026-03-31 |
Powered by Claude AI